目的:探讨川芎嗪注射液联合坎地沙坦酯治疗慢性肺源性心脏病急性加重期的临床疗效以及安全性.方法:筛选2015年6月~2016年6月某院收治的慢性肺心病急性加重期患者86例,作为研究对象.根据患者治疗方案将其分为观察组与对照组,其中对照组40例患者接受常规抗感染、吸氧、止咳平喘、纠正电解质紊乱等慢性肺心病急性加重期常规治疗,观察组46例则在对照组基础上联合应用川芎嗪以及坎地沙坦酯,比较两组患者治疗效果及不良反应发生情况.结果:观察组患者治疗后PaCO2、PaO2、血液黏度、红细胞压积指标明显优于对照组,P<0.05,差异具有统计学意义;观察组患者治疗总有效率明显高于对照组,P<0.05,具有统计学意义;两组患者治疗过程中均未发生严重不良反应.结论:在常规治疗基础上联合应用川芎嗪与坎地沙坦酯治疗慢性肺心病急性加重期疗效显著,可有效改善患者血气指标及血液流变学指标,并且治疗安全性较高,具有临床应用及推广价值.%Objective:To investigate the clinical efficacy and safety of ligustrazine injection combined with candesartan in the treatment of acute exacerbation of chronic pulmonary heart disease.Methods:86 patients with acute exacerbation of chronic pulmonary heart disease treated in a hospital from June 2015 to June 2016 were selected as the subjects.According to treatment plan,all patients were divided into observation group and control group,the 40 patients in the control group received conventional treatment for acute exacerbation of chronic pulmonary heart disease such as anti infection,oxygen inhalation,relieving cough and asthma,correct electrolyte disorders,the 46 patients in the observation group was given ligustrazine injection combined with candesartan cilexetil based on the control group,then the incidence of adverse reactions and treatment effects were compared between the two groups.Results:After treatment,the PaCO2, PaO2,blood viscosity,hematocrit indexes of observation group were significantly better than those of control group,P<0.05,with statistically significant difference;The total effective rate of observation group was significantly higher than that of control group,P<0.05,with statistical significance;There was no serious adverse reactions of two groups during the treatment.Conclusion:On the basis of routine treatment,the curative effect of ligustrazine combined with candesartan cilexetil in the treatment of patients with chronic pulmonary heart disease in acute exacerbation period can effectively improve the indexes of blood gas analysis and hemorheological indexes,with high treatment safety,which has clinical application and promotion value.
展开▼
